NEIVFQ-25中文版在老年性黄斑变性患者中应用的性能评价
|
摘要
目的对视功能相关生命质量量表(National Eye Institute 25-Item Visual Function Questionnaire,NEI VFQ-25)中文版在老年性黄斑变性(age-related macular degeneration,AMD)患者中的应用进行信度和效度评价。设计诊断试验。研究对象AMD患者107例及正常对照69例。方法分别利用健康危险因素调查问卷和中文版NEI VFQ-25对上述研究对象进行一般情况和视功能相关生存质量调查。根据受调查者的得分情况,采用内部一致性信度、分半信度评价量表信度,内容效度、结构效度和区分效度评价量表效度。主要指标信度和效度。结果结果显示量表的信度良好,总体Cronbachα信度系数、分半信度系数分别为0.83和0.77;探索性因子分析12个维度共得到3个公因子,累计方差贡献率为65.35%,表明量表结构效度良好;病例组、对照组在各维度得分不同(P<0.05),说明量表区分效度良好。结论中文版NEI VFQ-25量表在评价AMD患者视功能相关生存质量方面具有良好的信度和效度,适用于综合评价AMD所导致的视力损伤对生存质量的影响。
Objective To evaluate the reliability and validity of the Chinese version of the National Eye Institute 25-Item Visual Function Questionnaire(NEI VFQ-25) in aged-related macular degeneration(AMD) patients. Design Diagnostic test. Participants A total of 107 AMD patients and 69 controls were included. Methods The health risk factors questionnaire and the Chinese version of NEI VFQ-25 were used to examine the baseline characteristics and vision-related quality of life, respectively. According to the scores of subjects, the internal consistency reliability, split-half reliability, construct validity and discriminant validity were carried out to evaluate the validity of the questionnaire. Main Outcome Measures Reliability and validity. Results The reliability of the questionnaire was good,and the Cronbach'alpha coefficient and Spearman-Brown split-half coefficient were 0.827 and 0.772, respectively. Three common factors were extracted from 12 dimensionality by principal component analysis and the accumulated variance rate of contribution was 65.35%, suggesting a good construct validity. The discriminant validity test results between the AMD and control group were statistically significant in all the subscales of NEI VFQ-25(P<0.05), indicating a good discriminant validity of the questionnaire. Conclusion The Chinese version questionnaire of NEI VFQ-25 has good reliability and validity in evaluating the visual function damage for patients with AMD, which can be implemented as a good scale and evaluation tool for the life quality of those persons with AMD.
Objective To evaluate the reliability and validity of the Chinese version of the National Eye Institute 25-Item Visual Function Questionnaire(NEI VFQ-25) in aged-related macular degeneration(AMD) patients. Design Diagnostic test. Participants A total of 107 AMD patients and 69 controls were included. Methods The health risk factors questionnaire and the Chinese version of NEI VFQ-25 were used to examine the baseline characteristics and vision-related quality of life, respectively. According to the scores of subjects, the internal consistency reliability, split-half reliability, construct validity and discriminant validity were carried out to evaluate the validity of the questionnaire. Main Outcome Measures Reliability and validity. Results The reliability of the questionnaire was good,and the Cronbach'alpha coefficient and Spearman-Brown split-half coefficient were 0.827 and 0.772, respectively. Three common factors were extracted from 12 dimensionality by principal component analysis and the accumulated variance rate of contribution was 65.35%, suggesting a good construct validity. The discriminant validity test results between the AMD and control group were statistically significant in all the subscales of NEI VFQ-25(P<0.05), indicating a good discriminant validity of the questionnaire. Conclusion The Chinese version questionnaire of NEI VFQ-25 has good reliability and validity in evaluating the visual function damage for patients with AMD, which can be implemented as a good scale and evaluation tool for the life quality of those persons with AMD.
引文
[1]Lin LS,Mitchell P,Seddon JM,et al.Age-related macular degeneration.Lancet,2012,379(9827):1728-1738.
[2]Pascolini D,Mariotti SP.Global estimates of visual impairment:2010.Br J Ophthalmol,2012,96(5):614-618.
[3]Ye H,Zhang Q,Liu X,et al.Prevalence of age-related macular degeneration in an elderly urban Chinese population in China:the Jiangning Eye Study.Invest Ophth Vis Sci,2014,55(10):6374-6380.
[4]Zhang Y,Hu S,Chang J,et al.Burden of wet age-related macular degeneration in china.Value Health,2014,17(7):782-782.
[5]陈建华,徐亮,王研,等.北京市城乡限定地区人群视力损害和社会经济因素关系的调查.眼科,2004,13(6).360-364.
[6]Wong WL,Su X,Li X,et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040:a systematic review and meta-analysis.Lancet Glob Health,2014,2(2):106-116.
[7]Ferris FL,Wilkinson CP,Bird AC,et al.Clinical classification of age-related macular degeneration.Ophthalmology,2013,120(4):844-851.
[8]Cheung LK,Eaton A.Age-related macular degeneration.Pharmacotherapy,2013,33(8):838-855.
[9]Bravo Filho VT,Ventura RU,Brandt CT,el al.Visual impairment impact on the quality of life of the elderly population that uses the public health care system from the western countryside of Pernambuco State,Brazil.Arq Bras Oftalmol,2012,75(3):161-165.
[10]Clemons TE,Chew EY,Bressler SB,et al.National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study(AREDS):AREDS Report No.10.Arch Ophthalmol,2003,121(2):211-217.
[11]Marella M,Pesudovs K,Keeffe JE,et al.The psychometric validity of the NEI VFQ-25 for use in a low-vision population.Invest Ophth Vis Sci,2010,51(6):2878-2884.
[12]Mangione CM,Lee PP,Gutierrez PR,et al.Development of the25-item National Eye Institute Visual Function Questionnaire.Arch Ophthalmol,2001,119(7):1050-1058.
[13]张海瑞,马莉,任苒,等.视功能相关生命质量量表NEI VFQ-25中文版的研制及其性能评价.现代预防医学,2015,42(12):2211-2214.
[14]黄江.中文版视功能相关的生存质量量表-25的研制及初步应用评价.温州:温州医科大学,2007,12-31.
[15]Chan CW,Wong D,Lam CL,et al.Development of a Chinese version of the National Eye Institute Visual Function Questionnaire(CHI-VFQ-25)as a tool to study patients with eye diseases in Hong Kong.Br J Ophthalmol,2009,93(11):1431-1436.
[16]Gabrielian A,Hariprasad SM,Jager RD,et al.The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life.Eye,2010,24(1):29-35.
[17]Deramo VA,Cox TA,Syel AB,et al.Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire.Arch Ophthalmol,2003,121(9):1297-1302.
[18]Ma L,Dou H,Wu Y,et al.Lutein and zeaxanthin intake and the risk of age-related macular degeneration:a systematic review and meta-analysis,Brit J Nutr,2012,107(3):350-359.
[19]Campagne MV,Lecouter J,Yaspan BL,et al.Mechanisms of age-related macular degeneration and therapeutic opportunities.J Pathol,2014,232(2):151-164.
[20]Voleti VB,Hubschman JP.Age-related eye disease.Matufitas,2013,75(1):29-33.
[21]刘杰为,何明光.视功能生存质量评价量表.中国临床康复,2002,6(19):2835-2837.
[22]Rovner BW,Casten RJ,Hegel MT,et al.Low vision depression prevention trial in age-related macular degeneration:a randomized clinical trial.Ophthalmology,2014,121(11):2204-2211.
[2]Pascolini D,Mariotti SP.Global estimates of visual impairment:2010.Br J Ophthalmol,2012,96(5):614-618.
[3]Ye H,Zhang Q,Liu X,et al.Prevalence of age-related macular degeneration in an elderly urban Chinese population in China:the Jiangning Eye Study.Invest Ophth Vis Sci,2014,55(10):6374-6380.
[4]Zhang Y,Hu S,Chang J,et al.Burden of wet age-related macular degeneration in china.Value Health,2014,17(7):782-782.
[5]陈建华,徐亮,王研,等.北京市城乡限定地区人群视力损害和社会经济因素关系的调查.眼科,2004,13(6).360-364.
[6]Wong WL,Su X,Li X,et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040:a systematic review and meta-analysis.Lancet Glob Health,2014,2(2):106-116.
[7]Ferris FL,Wilkinson CP,Bird AC,et al.Clinical classification of age-related macular degeneration.Ophthalmology,2013,120(4):844-851.
[8]Cheung LK,Eaton A.Age-related macular degeneration.Pharmacotherapy,2013,33(8):838-855.
[9]Bravo Filho VT,Ventura RU,Brandt CT,el al.Visual impairment impact on the quality of life of the elderly population that uses the public health care system from the western countryside of Pernambuco State,Brazil.Arq Bras Oftalmol,2012,75(3):161-165.
[10]Clemons TE,Chew EY,Bressler SB,et al.National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study(AREDS):AREDS Report No.10.Arch Ophthalmol,2003,121(2):211-217.
[11]Marella M,Pesudovs K,Keeffe JE,et al.The psychometric validity of the NEI VFQ-25 for use in a low-vision population.Invest Ophth Vis Sci,2010,51(6):2878-2884.
[12]Mangione CM,Lee PP,Gutierrez PR,et al.Development of the25-item National Eye Institute Visual Function Questionnaire.Arch Ophthalmol,2001,119(7):1050-1058.
[13]张海瑞,马莉,任苒,等.视功能相关生命质量量表NEI VFQ-25中文版的研制及其性能评价.现代预防医学,2015,42(12):2211-2214.
[14]黄江.中文版视功能相关的生存质量量表-25的研制及初步应用评价.温州:温州医科大学,2007,12-31.
[15]Chan CW,Wong D,Lam CL,et al.Development of a Chinese version of the National Eye Institute Visual Function Questionnaire(CHI-VFQ-25)as a tool to study patients with eye diseases in Hong Kong.Br J Ophthalmol,2009,93(11):1431-1436.
[16]Gabrielian A,Hariprasad SM,Jager RD,et al.The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life.Eye,2010,24(1):29-35.
[17]Deramo VA,Cox TA,Syel AB,et al.Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire.Arch Ophthalmol,2003,121(9):1297-1302.
[18]Ma L,Dou H,Wu Y,et al.Lutein and zeaxanthin intake and the risk of age-related macular degeneration:a systematic review and meta-analysis,Brit J Nutr,2012,107(3):350-359.
[19]Campagne MV,Lecouter J,Yaspan BL,et al.Mechanisms of age-related macular degeneration and therapeutic opportunities.J Pathol,2014,232(2):151-164.
[20]Voleti VB,Hubschman JP.Age-related eye disease.Matufitas,2013,75(1):29-33.
[21]刘杰为,何明光.视功能生存质量评价量表.中国临床康复,2002,6(19):2835-2837.
[22]Rovner BW,Casten RJ,Hegel MT,et al.Low vision depression prevention trial in age-related macular degeneration:a randomized clinical trial.Ophthalmology,2014,121(11):2204-2211.